AMGN vs AZN Stock Comparison
AMGN currently leads AZN in this stock comparison, with AIQ scores of 63 vs 62. The clearest difference is momentum, while AZN has the stronger value profile.
What is the main difference between AMGN and AZN?
AMGN leads the current stock comparison as Amgen Inc., with the clearest separation coming from momentum and the broader AIQ evidence mix.
AlgovestIQ AIQ Comparison
Amgen Inc. vs AstraZeneca PLC
AMGN leads
AMGN leads by 1 AIQ points, primarily on Momentum, but the lead has narrowed from 9 points over 30 sessions. Wall Street currently favors AZN on target upside.
Fragile: 2 of 6 evidence groups support AMGN, its lead is narrowing, and its current signal state is conflicted.
Amgen Inc.
AstraZeneca PLC
The Algovestiq AIQ Score currently favors AMGN over AZN, 63 versus 62 as of Oct 31, 2026. AMGN's advantage is driven primarily by stronger momentum, while AZN holds the stronger value profile. AMGN also shows the weaker technical structure relative to its 50-day moving average, though analyst target upside currently favors AZN. 2 of 6 covered evidence groups favor AMGN today, and the comparison is rated Fragile on stability: the AIQ gap is narrow at 1 points. AMGN lead: Weakening — the AIQ differential moved from 9 to 1 points over 30 sessions.
Compare Amgen Inc. and AstraZeneca PLC across the Algovestiq AIQ Score, valuation, quality, momentum, risk, technicals and analyst expectations.
Performance over time
Total return with distributions reinvested, from daily closes.
Total return comparison
Growth of $10,000, distributions reinvested
Split-adjusted closes; each distribution is reinvested at the close on its ex-dividend date. Taxes and trading costs are not modeled.
Compare AMGN and AZN against another ticker
Open a multi-ticker workspace without changing this focused pair page.
AIQ Factor Divergence
Where the two separate, on the four dimensions behind the AIQ Score. Bars read outward from a shared zero: further from the centre is a wider gap.
- Momentum87 vs 73AMGN +14
- Value44 vs 52AZN +8
- Quality70 vs 72Even
- Risk Resilience46 vs 47Even
2 of 6 evidence groups favor AMGN. AMGN’s edge is concentrated in momentum; AZN keeps a meaningful value edge.
What changed since the last close
Latest scored session 2026-10-28, compared against the prior scored session 2026-10-27.
Largest factor move: Momentum +1, not enough on its own to move the overall score.
New signals
- RSI Overbought — bearish, momentum, short horizon
Largest factor move: Momentum +1, not enough on its own to move the overall score.
No signal started or stopped since the prior session; its 2 active signals are unchanged.
AMGN's lead was unchanged in the latest session.
Deeper signal detail for each name lives on its own signals page — AMGN and AZN both carry a full feed there.
The central trade-off
AMGN (Amgen Inc.): the stronger current systematic profile, led by momentum.
AZN (AstraZeneca PLC): the counter-case, on value, valuation, analyst expectations.
The AIQ Score and Wall Street therefore point in different directions on this pair.
Which one fits your objective
The same two names rank differently depending on what you are optimizing for. All six reads are shown at once — none of them is hidden behind a toggle.
Balanced
AMGNAMGN on the overall AIQ Score, which weights Quality and Value most heavily.
Growth
AMGNAMGN on combined revenue and EPS growth.
Value
AZNAZN on the peer-relative Value factor, by 8 points.
Momentum
AMGNAMGN on the Momentum factor, by 14 points.
Lower downside
AZNAZN carries the lower 1-month annualized volatility.
Analyst upside
AZNAZN on implied upside to the consensus price target.
AIQ vs Wall Street
The model and the Street disagree here: AIQ favors AMGN, analyst targets favor AZN. That disagreement is the most useful thing on this page.
| Measure | AMGN | AZN | Note |
|---|---|---|---|
| Implied upside to target | -14.8% | +15.7% | AZN has more room |
| Target dispersion | +68% | 0% | Lower is tighter analyst agreement |
| Consensus | Hold | Buy | Context, not a primary driver |
| Analysts covering | 19 | 1 | Higher coverage generally improves confidence |
The two are measuring different things. The AIQ Score reads current fundamentals, valuation, trend and risk; analyst targets price forward expectations. A divergence of this kind is either a contrarian opportunity or a sign the model is missing something already priced in — it is worth resolving before acting on either.
Analyst targets are expectations, not predictions. Dispersion matters as much as the midpoint.
Dividend growth
| Dividend metric | AMGN | AZN |
|---|---|---|
| 5Y dividend CAGR | 8.27% | 2.40% |
| 2020 regular DPS | $6.400 | $2.780 |
| 2025 regular DPS | $9.520 | $3.130 |
| Years increased | 5 | 4 |
| No cut in window | Yes | Yes |
| Cohort rank | #138 | #318 |
AMGN grew its split-adjusted regular dividend faster over 2020–2025 — 8.27% a year against AZN's 2.40%. Neither company reduced its regular dividend in any year of the window.
Yield and payout ratio shown elsewhere on this page are current values, not part of the study window.
Split-adjusted regular dividends per share, 2020–2025, excluding special dividends. Research as of Sep 19, 2026.
AIQ Agreement Matrix
2 of 6 covered evidence groups favor AMGN. A wide gap backed by one group is a weaker case than a narrow gap backed by five.
| Evidence group | Favors | Reading |
|---|---|---|
| AIQ Score | Even | 63 vs 62 |
| Fundamentals | AMGNon balance | EPS growth 30.6% vs -19.6%; TTM ROE 89.3% vs 21.7%; gross margin 72.7% vs 79.3%; operating margin 33.2% vs 22.7% — AMGN takes 3 of 4 decided legs, not all of them |
| Valuation | AZN | Value 44 vs 52 |
| Technicals | AMGN | Price vs 50-day 11.2% vs 13.9%; vs 200-day 21% vs -6% |
| Risk Resilience | Even | Risk Resilience 46 vs 47 |
| Analyst expectations | AZN | Target upside -14.8% vs 15.7% |
✓ agrees with the overall verdict · ✕ points the other way. Groups marked “not covered” lack data on one or both of AMGN and AZN and are excluded from the count.
AIQ Decision Stability
The conclusion is sensitive to small changes. Treat the lead as provisional and watch the flip conditions below.
- The AIQ gap is narrow at 1 points. (argues the conclusion is provisional)
- Only 2 of 6 covered evidence groups agree. (argues the conclusion is provisional)
- The leader's advantage has been narrowing. (argues the conclusion is provisional)
- The leader is throwing conflicting signals. (argues the conclusion is provisional)
- Analyst targets on the leader are widely dispersed. (argues the conclusion is provisional)
Stability combines the score gap, how broadly the evidence agrees, how steady the lead has been across daily snapshots, the current signal state on both names, and analyst dispersion on AMGN.
How the comparison changed
120 daily snapshots · Jun 29 – Oct 28AMGN lead: Weakening — the AIQ differential moved from 9 to 1 points over 30 sessions.
- Today
- AMGN +1
- 63 vs 62
- 7 sessions ago
- Level
- 63 vs 63
- 30 sessions ago
- AMGN +9
- 61 vs 52
- 90 sessions ago
- AMGN +5
- 63 vs 58
The lead changed hands 3 times in this window, most recently on Oct 19 when AZN moved ahead of AMGN.
AIQ Signal Divergence
Only the signals that bear on the head-to-head. A conflicted name is carrying bullish and bearish rules at the same time — the technical evidence is not pointing one way.
6 bullish / 1 bearish, conflicted
Only AMGN
- Golden Cross Active — bullish, trend, long horizon (12.19%)
- Keltner Channel Breakout — bullish, volatility, short horizon
- RSI Overbought — bearish, momentum, short horizon
- EMA Ribbon Expansion Bullish — bullish, trend, medium horizon
- 52-Week High Proximity — bullish, risk, long horizon (0.0%)
- Uptrend Structure Active — bullish, trend, long horizon
1 bullish / 1 bearish, conflicted
Only AZN
- Death Cross Active — bearish, trend, long horizon (10.02%)
Both carry 1 more signal that do not separate them: MACD Bullish Crossover.
AMGN leads the comparison while carrying a conflicted signal state, which is one reason the stability rating is not higher.
Price vs model alignment
Whether the latest session's price move confirms what the model did over the same session, or contradicts it.
Neither the price nor the AIQ Score moved enough in the latest session to confirm or contradict the other (price +1.15%, AIQ 0 points).
Neither the price nor the AIQ Score moved enough in the latest session to confirm or contradict the other (price +7.02%, AIQ 0 points).
What would flip this result
A state, not a forecast. These are the specific, observable changes that would reverse the verdict — not a price prediction.
- 1AZN closes the Momentum gap — currently 14 points behind, the largest single contributor to AMGN's edge.
- 2AZN's Death Cross Active resolves — a bearish trend rule currently active against it.
- 3AMGN's conflicting signal state resolves bearish — it currently carries 6 bullish and 1 bearish rules at once.
- 4The narrowing continues — the lead has already given back 8 points over 30 sessions, and a further 1-point move would eliminate AMGN's advantage entirely.
The full evidence
Every number behind the verdict. The leader is called above each group so you are not left to solve it from the table.
Fundamentals
AMGN leads on balance| Metric | AMGN | AZN |
|---|---|---|
| Revenue growth (YoY) | 16.7% | 0.6% |
| EPS growth (YoY) | 30.6% | -19.6% |
| Gross margin | 72.7% | 79.3% |
| Operating margin | 33.2% | 22.7% |
| Return on equity (TTM) | 89.3% | 21.7% |
| Debt to equity | 4.9 | 0.64 |
Performance
AMGN leads 6 of 6 windows| Metric | AMGN | AZN |
|---|---|---|
| 1 week (5 sessions) | 3.1% | 0.6% |
| 1 month (20 sessions) | 7.2% | 5% |
| 3 months (63 sessions) | 16.6% | -1.1% |
| 6 months (126 sessions) | 33.7% | -8.5% |
| Year to date | 35.8% | -7.8% |
| 1 year (252 sessions) | 54.9% | 1.8% |
Technicals
AMGN has the stronger structure| Metric | AMGN | AZN |
|---|---|---|
| RSI (14) | 74.9 | 67.3 |
| ADX (14) | 30.3 | 16.1 |
| Price vs 50-day | 11.2% | 13.9% |
| Price vs 200-day | 21% | -6% |
| Volatility (1M, annualized) | 28.6% | 26.5% |
Risk
Split| Metric | AMGN | AZN |
|---|---|---|
| Beta | 0.46 | 0.23 |
| Sharpe ratio | 1.49 | 0.09 |
| Sortino ratio | 2.28 | 0.14 |
| Max drawdown | -16.6% | -25.7% |
| Current drawdown | 0% | -19.1% |
| Annualized volatility | 29.6% | 27.3% |
| Value at risk (95%) | -2.3% | -2.5% |
Straight answers
Each answer is regenerated from the current snapshot, not written once and left to age.
Which is better, AMGN or AZN?
On the Algovestiq AIQ Score, AMGN is the stronger of the two as of Oct 31, 2026, scoring 63 against AZN's 62. The edge comes from momentum. AZN is not without a case — it holds the better value profile, which matters more if that is the objective you are optimizing for. This is a systematic score, not a recommendation: it ranks the two on the same evidence, it does not know your holding period or tax position.
Is AMGN or AZN the better buy right now?
AMGN carries the stronger systematic profile as of Oct 31, 2026, and the comparison is rated Fragile — 2 of 6 covered evidence groups agree. A Fragile rating means the conclusion is sensitive: the AIQ gap is narrow at 1 points. Treat the lead as provisional.
Why does the AIQ Score favor AMGN over AZN?
The composite weights Quality, Value, Momentum and Risk Resilience. AMGN leads Momentum by 14 points; AZN leads Value by 8 points. Where the two split, the factor with the larger weight carries the result.
Which has more analyst upside, AMGN or AZN?
Analyst price targets imply -14.8% upside for AMGN and +15.7% for AZN, so the Street currently favors AZN. That points the opposite way to the AIQ Score, which favors AMGN. The two are measuring different things: the model reads current fundamentals, valuation, trend and risk; the Street is pricing forward expectations. A divergence of this kind is either a contrarian opportunity or a sign the model is missing something the analysts have already priced — it is the single most useful row on this page to investigate. Analyst targets are expectations, not predictions, and dispersion matters as much as the midpoint.
Which is better value, AMGN or AZN?
AZN is the better-valued of the two on the peer-relative Value factor. AZN on the peer-relative Value factor, by 8 points. The Value factor reads valuation relative to sector peers and to the company's own fundamental quality, so it is not the same as simply having the lower multiple.
Which has stronger growth, AMGN or AZN?
AMGN on combined revenue and EPS growth. Growth here is measured on reported revenue and earnings, not on forward estimates — it describes what the businesses have delivered, not what the Street expects next.
Which has stronger momentum, AMGN or AZN?
AMGN on the Momentum factor, by 14 points. Momentum is one of the four weighted factors in the AIQ composite. It has documented persistence over three- to twelve-month horizons, which makes it a timing input rather than a reason to hold something indefinitely.
Which is riskier, AMGN or AZN?
AZN is the more resilient of the two, so the other name carries the higher downside risk. AZN carries the lower 1-month annualized volatility. Risk Resilience is a weighted factor in the composite; position sizing usually responds to it more usefully than the buy/avoid decision does.
Is AMGN more profitable than AZN?
The profitability evidence is mixed: gross margin 72.7% vs 79.3%; operating margin 33.2% vs 22.7%; ttm roe 89.3% vs 21.7%. AMGN leads on two measures and AZN on one measure, and there is no single profitability composite that resolves the split — which of the two reads as "more profitable" depends on whether you weight pricing power or operating leverage.
Is AMGN's lead over AZN getting stronger or weaker?
AMGN lead: Weakening — the AIQ differential moved from 9 to 1 points over 30 sessions. This is measured from 120 daily comparison snapshots between 2026-06-29 and 2026-10-28. The lead has changed hands 3 times in that window, most recently on 2026-10-19, when AZN moved ahead of AMGN.
What would change the AMGN vs AZN verdict?
The result is a state, not a forecast, so it changes when the underlying evidence changes. Concretely: AZN closes the Momentum gap — currently 14 points behind, the largest single contributor to AMGN's edge; AZN's Death Cross Active resolves — a bearish trend rule currently active against it; AMGN's conflicting signal state resolves bearish — it currently carries 6 bullish and 1 bearish rules at once; the narrowing continues — the lead has already given back 8 points over 30 sessions, and a further 1-point move would eliminate AMGN's advantage entirely.
What do the current signals say about AMGN and AZN?
AMGN: 6 bullish / 1 bearish, conflicted. AZN: 1 bullish / 1 bearish, conflicted. A conflicted state means bullish and bearish rules are active on the same name at once — the technical evidence is not pointing one way, and a decision taken on it carries more timing risk. The most decision-relevant rule on AMGN is Golden Cross Active (bullish, long horizon). On AZN it is Death Cross Active (bearish, long horizon).
Compare AMGN and AZN with others
Continue your research
This page answers which of the two. These answer the questions on either side of it.
How this comparison is scored
The Algovestiq AIQ Score composites four factors — Quality, Value, Momentum and Risk, each carrying a fixed weight. Sentiment is reported separately as SentimentPulse and is not folded into the composite. Scores refresh every trading day, and this page regenerates from the latest snapshot rather than being written once.
The verdict names a leader, states how broadly six independent evidence groups agree, and rates how durable that conclusion is given the score gap, its recent trajectory and the current signal state on both names.
How to use side-by-side comparison →This comparison is informational and educational, not investment advice. AIQ scores update daily; re-check after earnings, guidance or macro data that materially changes either name’s factor profile.